Lipid re-screening: What is the best measure and interval?

Heart

Volumn 96, Issue 6, 2010, Pages 448-452

  Takahashi, Osamu ^a,b   Glasziou, Paul P ^a   Perera, Rafael ^a   Shimbo, Takuro ^c   Suwa, Jiro ^b   Hiramatsu, Sonoe ^b   Fukui, Tsuguya ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b ST LUKE'S INTERNATIONAL HOSPITAL   (Japan)

^c NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; FEMALE; HEALTH PROGRAM; HUMAN; ISCHEMIC HEART DISEASE; JAPAN; MAJOR CLINICAL STUDY; MALE; MEDICAL EXAMINATION; OUTCOME ASSESSMENT; PREVENTIVE MEDICINE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCREENING TEST; SIGNAL NOISE RATIO; TRIACYLGLYCEROL BLOOD LEVEL; UNIVERSITY HOSPITAL;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY DISEASE; FEMALE; HUMANS; HYPERLIPIDEMIAS; JAPAN; LIPIDS; MALE; MASS SCREENING; MIDDLE AGED; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 77949639951     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/hrt.2009.172619     Document Type: Article

References (32)

1. Hyre AD, Muntner P, Menke A, et al. Trends in ATP-III-defined high blood cholesterol prevalence, awareness, treatment and control among U.S. adults. Ann Epidemiol 2007;17:548-55.
2. Arai H, Yamamoto A, Matsuzawa Y, et al. Prevalence of metabolic syndrome in the general Japanese population in 2000. J Atheroscler Thromb 2006;13:202-8.
3. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
4. Teramoto T, Sasaki J, Ueshima H, et al. Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese. J Atheroscler Thromb 2007;14:45-50.
5. Okamura T, Kokubo Y, Watanabe M, et al. Low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol and the incidence of cardiovascular disease in an urban Japanese cohort study: the Suita study. Atherosclerosis 2009;203:587-92.
6. Costa J, Borges M, David C, et al. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. BMJ 2006;332:1115-24.
7. Nakamura H, Arakawa K, Itakura H, et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet 2006;368:1155-63.
8. Pignone M, Phillips C, Mulrow C. Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomised trials. BMJ 2000;321:983-6.
9. MMWR. Trends in Cholesterol Screening and Awareness of High Blood Cholesterol - United States, 1991-2003. JAMA 2005;294:2021-2.
10. H.E.A.R.T UK - The Nation's Cholesterol Charity. Available at http://www.heartuk.org.uk (accessed 6 January 2010).
11. Del Mar C, Doust J, Glasziou PP. Clinical thinking; evidence, communication and decision-making Oxford (UK): Blackwell Publishing Ltd. BMJ Books, 2006.
12. Glasziou PP, Irwig L, Aronson JK. Evidence-based medical monitoring: from principles to practice Oxford (UK): Blackwell Publishing, BMJ books, 2008.
13. National Institute for Health and Clinical Excellence (NICE) Clinical guideline. Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease 2008. Available at http://www.nice.org.uk/nicemedia/pdf/CG67NICEguideline.pdf (accessed 6 January 2010).
14. Cooper A, O'Flynn N. Risk assessment and lipid modification for primary and secondary prevention of cardiovasucular disease: summary of NICE guidance. BMJ 2008;336:1246-8.
15. The U.S. Preventive Services Task Force (USPSTF). Screening for lipid disorders in adults, 2008. Available at http://www.ahrq.gov/CLINIC/uspstf/ uspschol.htm (accessed 6 January 2010).
16. Glasziou P, Irwig L, Mant D. Monitoring in chronic disease: a rational approach. BMJ 2005;330:644-8.
17. Glasziou PP, Irwig L, Heritier S, et al. Monitoring cholesterol levels: measurement error or true change? Ann Intern Med 2008;148:656-61.
18. Bell KJ, Irwig L, Craig JC, et al. Use of randomised trials to decide when to monitor response to new treatment. BMJ 2008;336:361-5.
19. Bell KJ, Hayen A, Macaskill P, et al. Mixed models showed no need for initial response monitoring after starting antihypertensive therapy. J Clin Epidemiol 2009;62:650-9.
20. Kinosian B, Glick H, Garland G. Cholesterol and coronary heart disease: predicting risks by levels and ratios. Ann Intern Med 1994;121:641-7.
21. Ridker PM, Rifai N, Cook NR, et al. Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA 2005;294:326-33.
22. Ingelsson E, Schaefer EJ, Contois JH, et al. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA 2007;298:776-85.
23. Shepard DS. Reliability of blood pressure measurements: implications for designing and evaluating programs to control hypertension. J Chronic Dis 1981;34:191-209.
24. Thompson SG, Pocock SJ. The variability of serum cholesterol measurements: implications for screening and monitoring. J Clin Epidemiol 1990;43:783-9.
25. Smith SJ, Cooper GR, Myers GL, et al. Biological variability in concentrations of serum lipids: sources of variation among results from published studies and composite predicted values. Clin Chem 1993;39:1012-22.
26. Rotterdam EP, Katan MB, Knuiman JT. Importance of time interval between repeated measurements of total or high-density lipoprotein cholesterol when estimating an individual's baseline concentrations. Clin Chem 1987;33:1913-15.
27. Choudhury N, Wall PM, Truswell AS. Effect of time between measurements on within-subject variability for total cholesterol and high-density lipoprotein cholesterol in women. Clin Chem 1994;40:710-15.
28. Pereira MA, Weggemans RM, Jacobs DR Jr, et al. Within-person variation in serum lipids: implications for clinical trials. Int J Epidemiol 2004;33:534-41.
29. Schectman G, Patsches M, Sasse EA. Variability in cholesterol measurements: comparison of calculated and direct LDL cholesterol determinations. Clin Chem 1996;42:732-7.
30. Lemieux I, Lamarche B, Couillard C, et al. Total cholesterol/HDL cholesterol ratio vs LDL cholesterol/HDL cholesterol ratio as indices of ischemic heart disease risk in men: the Quebec Cardiovascular Study. Arch Intern Med 2001;161:2685-92.
31. Prospective Studies Collaboration. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55000 vascular deaths. Lancet 2007;370:1829-39.
32. British Cardiac Society BHS, Diabetes UK, HEART UK, , et al. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005;91(Suppl 5):v1-52.